Our results suggested that: (a) the patients harboring uncommon EGFR Exon 19 delins mutations have different prognoses; (b) patients with advanced LADC and EGFR p.E746_S752delinsI may benefit from the treatment of Icotinib; (c) NGS testing is crucial for guiding clinical treatment decisions in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.